Brief: EU Approves Sanofi's Menquadfi To Treat Infants Against Invasive Meningococcal Disease
BRIEF-EU Approves Sanofi's Menquadfi To Treat Infants Against Invasive Meningococcal Disease Aug 4 (Reuters) - Sanofi SA SASY.PA:
SANOFI’S MENQUADFI APPROVED IN THE EU FOR USE IN INFANTS FROM AGE SIX WEEKS AGAINST INVASIVE MENINGOCOCCAL DISEASE
Source text: ID:nGNX9bjW8t
Further company coverage: SASY.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
EdenTree fund manager Hiorns has bought up French stocks despite civil unrest (updated)
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments